RenovoRx Q2 2024 Earnings Report

RenovoRx EPS Results

• Actual EPS: -$0.10
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

RenovoRx Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

RenovoRx Announcement Details

• Quarter: Q2 2024
• Date: 8/13/2024
• Time: N/A
• Conference Call Date: Tuesday, August 13, 2024
• Conference Call Time: 7:00AM ET

RenovoRx (NASDAQ:RNXT) is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors. By leveraging a patented catheter design, the system enables localized drug perfusion through arterial infusion, potentially enhancing tumor uptake of chemotherapeutic agents. RenovoRx has also entered strategic collaborations to advance its clinical programs, including licensing arrangements for development and commercialization in select international markets.

Headquartered in Little Silver, New Jersey, RenovoRx conducts its clinical development activities through a network of investigative sites across the United States. The company’s management team comprises seasoned professionals with experience in interventional oncology, medical device development and regulatory affairs. As a Nasdaq-listed entity trading under the symbol RNXT, RenovoRx continues to advance its pipeline toward pivotal studies with the goal of offering new treatment options for patients with limited therapeutic alternatives.